Braveheart Bio charts path to independence through Nasdaq debut
The centerpiece of Braveheart’s strategy is BHB-1893, an oral cardiac myosin inhibitor treating hypertrophic cardiomyopathy (HCM). HCM is a genetic condition where abnormal heart muscle thickening disrupts blood flow and heightens risks of dangerous arrhythmias and sudden death. The condition comes in more severe obstructive (oHCM) and less severe nonobstructive (nHCM) subtypes.
This asset arrived through a licensing agreement with Jiangsu Hengrui Pharmaceuticals in September 2025 worth up to $1 billion. The initial public offering (IPO) filing did not disclose how much the firm is looking to raise. However, it did detail that Braveheart will use the capital to advance BHB-1893.
Hengrui’s drug development engine has become a launchpad for multiple US biotechs. Obesity-focused firm Kailera Therapeutics shattered IPO records earlier this year and similarly built its foundation on Hengrui-licensed compounds.
Braveheart secured $185 million in Series A financing following the Hengrui deal. The syndicate included players like Andreessen Horowitz, Forbion, OrbiMed, Enavate Sciences, and Frazier Life Sciences.
Braveheart and Hengrui unveiled encouraging Phase II results (NCT06516068) for BHB-1893 across both major HCM subtypes earlier in 2026. Armed with Phase II momentum, Braveheart plans to kick off worldwide Phase III studies for HCM populations. The oHCM trial is expected to begin in the latter half of 2026, while the nHCM study will follow in early 2027. Meanwhile, Hengrui is already running its own Phase III trial (NCT07021976) in China.
Braveheart joins a busy IPO calendar for 2026. In the past ten days the industry has seen filings from Scribe Therapeutics, Apnimed, and Attovia Therapeutics.
Braveheart will trade under the ticker BRVE.
